Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Updated daily

Drug recalls

Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.

Class IIOngoingDec 18, 2024Levothyroxine Sodium TabletsSubpotent and Superpotent DrugMylan Institutional, Inc. · D-0136-2025Class IIOngoingDec 18, 2024Levothyroxine Sodium TabletsSubpotent and Superpotent DrugMylan Institutional, Inc. · D-0135-2025Class IIOngoingDec 18, 2024Levothyroxine Sodium TabletsSubpotent and Superpotent DrugMylan Institutional, Inc. · D-0134-2025Class IIOngoingDec 18, 2024Levothyroxine Sodium TabletsSubpotent and Superpotent DrugMylan Institutional, Inc. · D-0133-2025Class IIOngoingDec 18, 2024Levothyroxine Sodium TabletsSubpotent and Superpotent DrugMylan Institutional, Inc. · D-0132-2025Class IIOngoingDec 18, 2024Levothyroxine Sodium TabletsSubpotent and Superpotent DrugMylan Institutional, Inc. · D-0131-2025Class IIOngoingDec 18, 2024Dabigatran EtexilateCGMP Deviations: Presence of N-nitroso-Dabigatran impurity above recommended interim limitAscend Laboratories, LLC · D-0130-2025Class IIOngoingDec 18, 2024Dabigatran EtexilateCGMP Deviations: Presence of N-nitroso-Dabigatran impurity above recommended interim limitAscend Laboratories, LLC · D-0129-2025Class IIOngoingDec 18, 2024Levothyroxine Sodium Tablets USPSuperpotent Drug and Subpotent Drug: potency failures obtainedViatris Inc · D-0128-2025Class IIOngoingDec 18, 2024Levothyroxine Sodium Tablets USPSuperpotent Drug and Subpotent Drug: potency failures obtainedViatris Inc · D-0127-2025Class IIOngoingDec 18, 2024Levothyroxine Sodium Tablets USPSuperpotent Drug and Subpotent Drug: potency failures obtainedViatris Inc · D-0126-2025Class IIOngoingDec 18, 2024Levothyroxine Sodium Tablets USPSuperpotent Drug and Subpotent Drug: potency failures obtainedViatris Inc · D-0125-2025Class IIOngoingDec 18, 2024Levothyroxine Sodium Tablets USPSuperpotent Drug and Subpotent Drug: potency failures obtainedViatris Inc · D-0124-2025Class IIOngoingDec 18, 2024Levothyroxine Sodium Tablets USPSuperpotent Drug and Subpotent Drug: potency failures obtainedViatris Inc · D-0123-2025Class IIOngoingDec 18, 2024Levothyroxine Sodium Tablets USPSuperpotent Drug and Subpotent Drug: potency failures obtainedViatris Inc · D-0122-2025Class IIOngoingDec 18, 2024Levothyroxine Sodium Tablets USPSuperpotent Drug and Subpotent Drug: potency failures obtainedViatris Inc · D-0121-2025Class IIOngoingDec 18, 2024Levothyroxine Sodium Tablets USPSuperpotent Drug and Subpotent Drug: potency failures obtainedViatris Inc · D-0120-2025Class IIOngoingDec 18, 2024Levothyroxine Sodium Tablets USPSuperpotent Drug and Subpotent Drug: potency failures obtainedViatris Inc · D-0119-2025Class IIOngoingDec 18, 2024Levothyroxine Sodium Tablets USPSuperpotent Drug and Subpotent Drug: potency failures obtainedViatris Inc · D-0118-2025Class IIIOngoingDec 18, 2024JavygtorFailed Impurities/Degradation SpecificationsDr. Reddy's Laboratories, Inc. · D-0117-2025Class IITerminatedDec 18, 2024Hylenex recombinantcGMP Deviations: Temperature excursionMckesson Medical-Surgical Inc. Corporate Office · D-0116-2025Class IITerminatedDec 18, 2024Kirkland Severe Cold & Flu Plus Congestion: Day - 112 coated caplets blister packCGMP Deviations: Released product should have been rejected.LNK International, Inc. · D-0115-2025Class IIOngoingDec 18, 2024Timolol Maleate Ophthalmic Solution USPDefective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle.FDC Limited · D-0114-2025Class IIITerminatedDec 18, 2024VarithenaDefective Delivery System: incorrect silicone oil-free NormJect 10 mL Luer Lock Solo syringes packaged in the pack, instead of the required silicone oil-free NormJect 10...Biocompatibles UK, Ltd. · D-0113-2025Class IITerminatedDec 11, 2024Lisdexamfetamine Dimesylate CapsulesFailed Content Uniformity Specifications: Product failed to meet the action limits for stratified content uniformity.Lannett Company Inc. · D-0112-2025Class IIOngoingDec 11, 202410 Irregular PigmentationCGMP Deviations: Inconsistency in the water systems.Generitech Corporation · D-0111-2025Class IIOngoingDec 11, 2024Cinacalcet TabletsCGMP deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso-Cinacalcet above acceptable intake limit.AvKARE · D-0110-2025Class IIOngoingDec 11, 2024Cinacalcet TabletsCGMP deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso-Cinacalcet above acceptable intake limit.AvKARE · D-0109-2025Class IIOngoingDec 11, 2024Cinacalcet TabletsCGMP deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso-Cinacalcet above acceptable intake limit.AvKARE · D-0108-2025Class IIOngoingDec 11, 2024Duloxetine DR Capsules USP 60 mgCGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limitRising Pharma Holding, Inc. · D-0107-2025Class IIOngoingDec 11, 2024Duloxetine Delayed-Release Capsules USPCGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limitRising Pharma Holding, Inc. · D-0106-2025Class IIOngoingDec 11, 2024Duloxetine Delayed-Release Capsules USPCGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limitRising Pharma Holding, Inc. · D-0105-2025Class IIOngoingDec 11, 2024Sunitinib Malate CapsulesLabeling: Label Mix-UpAvKARE · D-0104-2025Class IIOngoingDec 11, 2024Sunitinib Malate CapsulesLabeling: Label Mix-UpAvKARE · D-0103-2025Class IIIOngoingDec 11, 2024Esomeprazole Magnesium for Delayed-Release Oral Suspension 40 mgLabeling: Not Elsewhere Classified - Wrong NDC numberZydus Pharmaceuticals (USA) Inc · D-0102-2025Class IIOngoingDec 11, 2024Duloxetine Delayed-Release CapsulesCGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limitAmerisource Health Services LLC · D-0101-2025Class IIOngoingDec 11, 2024Duloxetine Delayed-Release CapsulesCGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limitAmerisource Health Services LLC · D-0100-2025Class IIOngoingDec 11, 2024Duloxetine Delayed-Release CapsulesCGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limitAmerisource Health Services LLC · D-0099-2025Class IIOngoingDec 11, 2024Diltiazem Hydrochloride Extended-Release CapsulescGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.Glenmark Pharmaceuticals Inc., USA · D-0098-2025Class IIOngoingDec 11, 2024Diltiazem Hydrochloride Extended-Release CapsulescGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.Glenmark Pharmaceuticals Inc., USA · D-0097-2025

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.